Dr. Baas on Next Steps in the Treatment of Mesothelioma

Paul Baas, MD
Published: Thursday, Aug 18, 2016



Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.

He maintains that chemotherapy will continue to be extremely relevant in mesothelioma given its efficacy and moderate toxicity. He also highlights that immunotherapy will continue to play a role in this field.

In terms of the differentiation of subtypes of mesothelioma, Baas discusses the identification of groups of patients that may benefit from arginine deprivation treatment, especially in the sarcomatoid type.


Paul Baas, MD, professor, Department of Thoracic Oncology, Netherlands Cancer Institute, discusses the future of treatment in mesothelioma.

He maintains that chemotherapy will continue to be extremely relevant in mesothelioma given its efficacy and moderate toxicity. He also highlights that immunotherapy will continue to play a role in this field.

In terms of the differentiation of subtypes of mesothelioma, Baas discusses the identification of groups of patients that may benefit from arginine deprivation treatment, especially in the sarcomatoid type.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x